AZRX vs. COCP, MIRA, BOLT, OKUR, MEIP, TRAW, AFMD, BFRG, CARM, and PVLA
Should you be buying AzurRx BioPharma stock or one of its competitors? The main competitors of AzurRx BioPharma include Cocrystal Pharma (COCP), MIRA Pharmaceuticals (MIRA), Bolt Biotherapeutics (BOLT), OnKure Therapeutics (OKUR), MEI Pharma (MEIP), Traws Pharma (TRAW), Affimed (AFMD), Bullfrog AI (BFRG), Carisma Therapeutics (CARM), and Palvella Therapeutics (PVLA). These companies are all part of the "medical" sector.
AzurRx BioPharma vs.
Cocrystal Pharma (NASDAQ:COCP) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, community ranking, media sentiment and valuation.
Cocrystal Pharma's return on equity of -94.62% beat AzurRx BioPharma's return on equity.
AzurRx BioPharma received 202 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 76.67% of users gave Cocrystal Pharma an outperform vote while only 74.26% of users gave AzurRx BioPharma an outperform vote.
6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 6.3% of AzurRx BioPharma shares are owned by institutional investors. 25.6% of Cocrystal Pharma shares are owned by insiders. Comparatively, 7.3% of AzurRx BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Cocrystal Pharma currently has a consensus price target of $7.00, indicating a potential upside of 258.06%. Given Cocrystal Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Cocrystal Pharma is more favorable than AzurRx BioPharma.
In the previous week, Cocrystal Pharma had 1 more articles in the media than AzurRx BioPharma. MarketBeat recorded 1 mentions for Cocrystal Pharma and 0 mentions for AzurRx BioPharma. AzurRx BioPharma's average media sentiment score of 0.00 beat Cocrystal Pharma's score of -0.33 indicating that AzurRx BioPharma is being referred to more favorably in the news media.
Cocrystal Pharma has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.
Cocrystal Pharma is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks.
Summary
Cocrystal Pharma beats AzurRx BioPharma on 12 of the 15 factors compared between the two stocks.
Get AzurRx BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AzurRx BioPharma Competitors List
Related Companies and Tools
This page (NASDAQ:AZRX) was last updated on 1/22/2025 by MarketBeat.com Staff
Free AZRX Stock Alerts